Low-density lipoprotein (ldl) apheresis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood. This specialized adjunctive procedure is reserved for patients who have severe refractory hypercholesterolemia after treatment with maximally tolerated LDL-lowering medications in combination with lifestyle changes, most often in the context of the genetic disorder familial hypercholesterolemia (FH). It is estimated that 2–4 % of patients with FH meet the criteria for initiating LDL apheresis, which means that about 1 in 12,500 to 1 in 50,000 individuals may be candidates for LDL apheresis. The approximately 3-h procedure acutely lowers the plasma LDL cholesterol concentration by up to 85 %, as well as lowering the concentrations of Lp(a) and remnant lipoproteins. The procedure has several documented cardiovascular benefits, including a 72 % reduction in cardiovascular events compared to standard medical therapy in a long-term open label trial.

Original languageEnglish (US)
Title of host publicationDyslipidemias: Pathophysiology, Evaluation and Management
PublisherHumana Press Inc.
Pages483-497
Number of pages15
ISBN (Print)9781607614241, 9781607614234
DOIs
Publication statusPublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Duell, P. (2015). Low-density lipoprotein (ldl) apheresis. In Dyslipidemias: Pathophysiology, Evaluation and Management (pp. 483-497). Humana Press Inc.. https://doi.org/10.1007/978-1-60761-424-1_29